Galapagos NV

Galapagos NV reported promising Phase 2 results for GLPG5101, a CAR T-cell therapy for mantle cell lymphoma, showing 100% objective response rate and 96% complete response rate with minimal toxicity. However, the company intends to wind down its cell therapy activities.

Galapagos NV plans to split its operations into two entities - SpinCo and the core Galapagos company. SpinCo will focus on developing innovative medicines through strategic deals, while Galapagos will focus on its global cell therapy leadership in oncology. The restructuring will result in job cuts and reduced annual cash burn.

Belgian stocks closed higher on Monday, with the BEL 20 index rising 1.37%. The top performers were Galapagos NV, UCB SA, and D'Ieteren NV, while Proximus NV, Aperam SA, and Argen-X declined.

The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

David Einhorn's GLRE 13F stock portfolio value increased from $1.49B to $1.75B this quarter. The largest 3 positions are at ~48% of the portfolio.